CLINICAL TRIALS PROFILE FOR XEOMIN

All Clinical Trials for Xeomin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00406367 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-10-01	Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period.
NCT00407030 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-07-01	At baseline patients received incobotulinumtoxinA (Xeomin) or placebo. Thereafter, all patients who entered the extension period were treated with up to five injection sessions of incobotulinumtoxinA (Xeomin) during the extension period.
NCT00430963 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-10-01	IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, IncobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for aesthetic treatment of facial lines. This study investigated the efficacy and safety of IncobotulinumtoxinA (Xeomin) in the treatment of glabellar frown lines compared to placebo. The study consisted of a Main Period and an Open-Label Extension [OLEX] Period of 120 days each.
NCT00432666 ↗	IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb	Completed	Merz Pharmaceuticals GmbH	Phase 3	2006-06-01	IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin. Injected into the muscle, incobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for treatment of various neurological conditions. This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of post-stroke spasticity of the upper limb.
NCT00465738 ↗	IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity	Completed	Merz Pharmaceuticals GmbH	Phase 3	2007-02-01	This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of arm tightness (upper limb spasticity) using two different dilutions of incobotulinumtoxinA (Xeomin).

Clinical Trial Conditions for Xeomin

Condition Name

Condition Name for Xeomin
Intervention	Trials
Glabellar Frown Lines	4
Cerebral Palsy	3
Stroke	3
Moderate to Severe Glabellar Frown Lines	3

Condition MeSH

Condition MeSH for Xeomin
Intervention	Trials
Muscle Spasticity	10
Cerebral Palsy	5
Stroke	5
Tremor	5

Clinical Trial Locations for Xeomin

Trials by Country

Trials by Country for Xeomin
Location	Trials
United States	95
Germany	15
Canada	14
Russian Federation	9
Poland	8

Trials by US State

Trials by US State for Xeomin
Location	Trials
Florida	10
California	9
New York	8
Tennessee	7
Pennsylvania	5

Clinical Trial Progress for Xeomin

Clinical Trial Phase

Clinical Trial Phase for Xeomin
Clinical Trial Phase	Trials
Phase 4	13
Phase 3	24
Phase 2	19

Clinical Trial Status

Clinical Trial Status for Xeomin
Clinical Trial Phase	Trials
Completed	37
Not yet recruiting	13
Recruiting	8

Clinical Trial Sponsors for Xeomin

Sponsor Name

Sponsor Name for Xeomin
Sponsor	Trials
Merz Pharmaceuticals GmbH	31
Merz North America, Inc.	7
Merz Pharmaceuticals, LLC	5

Sponsor Type

Sponsor Type for Xeomin
Sponsor	Trials
Other	52
Industry	51
U.S. Fed	1